Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Peinan Lin"'
Autor:
Xiao Han, Ying Wang, Jing Sun, Tao Tan, Xiaomin Cai, Peinan Lin, Yang Tan, Bingfeng Zheng, Biao Wang, Jiawei Wang, Lingyan Xu, Zhengyi Yu, Qiang Xu, Xingxin Wu, Yanhong Gu
Publikováno v:
EBioMedicine, Vol 48, Iss , Pp 169-177 (2019)
Background: Tumor mutations and tumor microenvironment are associated with resistance to cancer immunotherapies. However, peripheral T cell in effective anti-programmed death 1 (PD-1) antibody treatment is poorly understood. Methods: Mass spectrometr
Externí odkaz:
https://doaj.org/article/e0ceda527937475f87fa41d0a6ff68a8
Autor:
Zhu Mei, Yang W. Shao, Peinan Lin, Xiaomin Cai, Biao Wang, Yan Ding, Xiangyuan Ma, Xue Wu, Yewei Xia, Dongqin Zhu, Yongqian Shu, Zan Fu, Yanhong Gu
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Cetuximab, an anti-EGFR monoclonal antibody, is used in combination with chemotherapy in clinic to enhance the outcome in metastatic colorectal cancer (mCRC) patients with only ~ 20% response rate. To date only activating mutation
Externí odkaz:
https://doaj.org/article/b57a6e013637421bb6adcef3410a58d8
Autor:
Biao Wang, Xiao Han, Lingyan Xu, Yang Tan, Peinan Lin, Zhengyi Yu, Bingfeng Zheng, Jing Sun, Jiawei Wang, Qiang Xu, Xiaomin Cai, Xingxin Wu, Tao Tan, Yanhong Gu, Ying Wang
Publikováno v:
EBioMedicine
Background Tumor mutations and tumor microenvironment are associated with resistance to cancer immunotherapies. However, peripheral T cell in effective anti-programmed death 1 (PD-1) antibody treatment is poorly understood. Methods Mass spectrometry
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5906dac41c7ee56970b4ce2035fcef03
http://europepmc.org/articles/PMC6838359
http://europepmc.org/articles/PMC6838359
Autor:
Biao Wang, Yewei Xia, Xue Wu, Yanhong Gu, Yongqian Shu, Xiaomin Cai, Zan Fu, Xiangyuan Ma, Dongqin Zhu, Zhu Mei, Peinan Lin, Yan Ding, Yang W. Shao
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
BMC Cancer
BMC Cancer
Background Cetuximab, an anti-EGFR monoclonal antibody, is used in combination with chemotherapy in clinic to enhance the outcome in metastatic colorectal cancer (mCRC) patients with only ~ 20% response rate. To date only activating mutations in KRAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0386cc90fd76d2c254bbfc12218e4d2a
http://link.springer.com/article/10.1186/s12885-018-4298-5
http://link.springer.com/article/10.1186/s12885-018-4298-5
Autor:
Biao Wang, Tianzhu Qiu, Xiaofeng Chen, Yanhong Gu, Ping Li, Hua Jiang, Fengjiao Zhao, Jing Sun, Peinan Lin, Yongqian Shu, Lianpeng Chang, Yingwei Zhu, Xiaomin Cai, Xiao Han
Publikováno v:
The Oncologist
Lessons Learned Patients with metastatic colorectal cancer with good performance status or no liver metastasis could benefit from apatinib. Circulating tumor DNA abundance may be a predictor in serial monitoring of tumor load. Background Apatinib, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::597883afdb4e5e81269192f11f095977
https://pubmed.ncbi.nlm.nih.gov/30877190
https://pubmed.ncbi.nlm.nih.gov/30877190
Autor:
Xiaomin Cai, Lingyan Xu, Shuhui Si, Haiwei Yang, Peinan Lin, Xiao Han, Yanhong Gu, Feng Wang, Zhiqiang Qin, Lele Li
Publikováno v:
Bioscience Reports
The association between methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer (CRC) susceptibility has been researched in numerous studies. However, the results of these studies were controversial. Therefore, the object
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::784966486b5641dbb504a7b091677c50
https://doi.org/10.1042/bsr20170917
https://doi.org/10.1042/bsr20170917
Autor:
Lele Li, Oluf Dimitri Røe, Xiaofeng Chen, Yiqian Liu, Chong Liu, Yongqian Shu, Xiaomin Cai, Shaohua He, Xiao Li, Ping Li, Jing Sun, Yanhong Gu, Jing Qian, Peinan Lin
Publikováno v:
Journal of Carcinogenesis & Mutagenesis.
Objective: This retrospective study was carried out to compare the safety and efficacy of adjuvant capecitabine/ oxaliplatin (XELOX) versus capecitabine/paclitaxel (XP) in gastric cancer patients after D2 gastrectomy. Methods: The hospital records of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc4b73759316060a5782e5ca42eaa5bc
https://doi.org/10.4172/2157-2518.1000306
https://doi.org/10.4172/2157-2518.1000306
Autor:
Xudong Wu, Peinan Lin, Xiu Chen, Yong Wang, Tao Tan, Yanhong Gu, Jing Sun, Yang Tan, Zhengyi Yu, Qiang Xu, Xiaomin Cai, Xiaodong Han, Biao Wang, Jiawei Wang
Publikováno v:
Annals of Oncology. 29:viii425-viii426
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::031841564829a89158046405845e0b24
https://doi.org/10.1093/annonc/mdy288.069
https://doi.org/10.1093/annonc/mdy288.069
Publikováno v:
Journal of Clinical Oncology. 36:3556-3556
3556Background: Apatinib, an oral VEGFR2 inhibitor, has been approved as third line treatment for metastatic gastric cancer in China. The aim of this study was to evaluate the efficacy and safety o...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1d1673a6ff5245e2400094aea6f5be1
https://doi.org/10.1200/jco.2018.36.15_suppl.3556
https://doi.org/10.1200/jco.2018.36.15_suppl.3556
Autor:
Lingyan Xu, Zhiqiang Qin, Feng Wang, Shuhui Si, Lele Li, Peinan Lin, Xiao Han, Xiaomin Cai, Haiwei Yang, Yanhong Gu
Publikováno v:
Bioscience Reports; Nov2017, Vol. 37 Issue 6, p1-15, 15p, 3 Diagrams, 2 Charts, 2 Graphs